Tag

Dr. Amit Panday is said to be one of the finest oncologists in Lucknow, working on cancer treatment, and taking proper care of patients with supreme care. Dr. Pandey, with 7+ years of experience and graduation, has helped more than 1000 cancer patients by giving a personalized and prioritized treatment plan based on the well-being of a patient. With a soft-hearted approach and dedication to providing the latest therapies, Dr. Amit Panday is the best cancer specialist in Lucknow.

Mahatma Gandhi Cancer Hospital & Research Institute is a well-established center of excellence for comprehensive cancer care and prevention. Being one of the best cancer institutes in India, it provides seamless cancer care under one roof through services like diagnostics, and state-of-the-art therapies that include Surgery, Chemotherapy, Radiotherapy, RadioIodine therapy, and Pain & Symptom Management to meet the needs of oncology patients. It promises a patient-centered approach to cure, improving the quality of life, and restoring hope. We offer compassionate care, a comfortable and friendly environment tailored to suit the needs of all cancer patients.

Parkway Cancer Centre offers comprehensive cancer treatment in Singapore with a highly skilled, multi-disciplinary team comprising consultant medical specialists, nurses, counsellors and other para-medical professionals to meet the specific needs of cancer patients.

Dr Smith is a Medical Director for Europe having joined Theradex® in February 2010.

He has background training in Medical Oncology with 15 years’ clinical practice experience. He is a graduate of the Royal College of Surgeons in Ireland and completed his postgraduate training in St Bartholomew and the Royal Marsden hospital. 

Dr Smith joined the industry with PPD as Lead Medical Director for Oncology (ex-US). His responsibilities at Theradex® include evaluation of the clinical, commercial feasibility and project strategy with clients; protocol development; and selecting and liaising with clinical investigators during the clinical trial progress. He is also responsible for assessing AE and SAEs for selected European studies, commenting and preparing narrative reports for onward reporting to clients, regulatory agencies, investigators and ethics committees as necessary.

Dr Smith is also responsible for medical review of data emerging from clients’ clinical trials and for advising clients on appropriate action to be taken based on the emerging data and to advise on risk management especially risk mitigation.

Dr Smith also has experience in early access patient schemes and advising on integrating market access programs in the product lifecycle development.

Dr Smith is a member of both American Society of Clinical Oncologists and European Society of Medical Oncology.

Charlie Gourley graduated with honours in Genetics from the University of Glasgow in 1991. He then went on to qualify as a medical doctor in 1994 also at the University of Glasgow.

Charlie progressed through his medical training in Edinburgh, continuously combining that with active research interests. He has successfully held research positions both at the University of Edinburgh and within the NHS.

Charlie’s career ladder took him to his current position as a Professor and Honorary Consultant in Medical Oncology, specialising in gynaecological cancers. He leads a clinical research team at the Edinburgh Cancer Centre, and a translational research group at the University of Edinburgh Cancer Research UK Centre.

He is a member of the National Cancer Research Network gynaecological cancers clinical studies group, the National Cancer Research Network ovarian subgroup and the Scottish Gynaecological Cancers Trials Group. He is also an active member of several other committees.

Following medical training and subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship in 1999 at Cambridge University and held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.

She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 and became Director of Imperial’s Early Cancer Trials Unit and established her laboratory studying the dysregulation of mRNA translation in cancer. She has been chief or principal investigator for a number of national and international clinical studies.